{"url":"https://lda.senate.gov/api/v1/filings/c19b66f3-5b5f-4050-93cc-2e8db1e8838b/","filing_uuid":"c19b66f3-5b5f-4050-93cc-2e8db1e8838b","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2010,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c19b66f3-5b5f-4050-93cc-2e8db1e8838b/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Mark T. Battaglini, Esq.","dt_posted":"2010-04-19T17:36:11.717000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"65 Hayden Avenue","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Lexington","registrant_state":"MA","registrant_zip":"02421","registrant":{"id":40026226,"url":"https://lda.senate.gov/api/v1/registrants/40026226/","house_registrant_id":39875,"name":"CUBIST PHARMACEUTICALS, INC.","description":"pharmaceutical company","address_1":"65 Hayden Avenue","address_2":null,"address_3":null,"address_4":null,"city":"Lexington","state":"MA","state_display":"Massachusetts","zip":"02421","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK BATTAGLINI","contact_telephone":"+1 781-860-8660","dt_updated":"2022-04-06T16:06:43.954054-04:00"},"client":{"id":188177,"url":"https://lda.senate.gov/api/v1/clients/188177/","client_id":75,"name":"CUBIST PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-02-18"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 4872 Health Care and Education Reconciliation Act of 2010, included amendments to the Health Reform package, H.R. 3590, altering provisions around the 340B program, taxes on the pharmaceutical industry, among other provisions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":44486,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"THOMAS","last_name":"BATTAGLINI","suffix":"esq","suffix_display":"ESQ"},"covered_position":"Mike Enzi, Sr. Senator WY, Congressional Fellow","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 610 Patent Reform Act of 2009 -Includes provisions which would expand the opportunities to challenge and invalidate a patent\nthrough the Patent & Trademark Office\nH.R. 1706 Patent Settlements\nS. 369 Preserve Access to Affordabe Generics Act, Patent Settlements S. 515 Patent Reform Act of 2009 - Includes provisions which would expand the opportunities to challenge and invalidate a patent through the Patent & Trademark Office.  The Senate Judiciary has been continuing negotiations to move forward with this bill as a reform package moving towards eventual Senate Floor consideration.\nH.R. 1260 Patent Reform Act of 2009  - Legislation to limit settlements of patent litigation between innovator and generic drug\ncompanies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":44486,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"THOMAS","last_name":"BATTAGLINI","suffix":"esq","suffix_display":"ESQ"},"covered_position":"Mike Enzi, Sr. Senator WY, Congressional Fellow","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Medical Research\nAntibiotic Resistance Issues\nH.R. 3590 Patient Protection and Affordable Care Act\nH.R. 4872 Health Care and Education Reconciliation Act of 2010 H.R. 2872 Health Care and Education Affordability Reconciliation Act\nH.R. 4213 Workers, State, and Business Relief Act of 2010\nH.R. 2847 Hiring Incentives to Restore Employment Act\nH.R. 4851 Continuing Extension Act of 2010\nH.R. 3200 Health Care Reform\nH.R. 3962 Health Care Reform\nS. 1796 Health Care Reform\nS. 525 Drug Reimportation\nH.R. 1298 Drug Reimportation\nH.R. 3590 Tax on Pharmaceutical Companies\nS. 1796 Tax on Pharmaceutical Companies\nS. 301 Physicians Payments\nH.R. 1427 Biosimilar Drugs\nH.R. 1548 Biosimilar Drugs\nS. 726 Biosimilar Drugs\nH.R. 1191 Disposal of Drugs\nH.R. 1359 Disposal of Drugs\nS. 1292 Disposal of Drugs\nS. 1336 Disposal of Drugs\nAnti-counterfeiting legislation concerning drugs (pedigree)\nPrescription Drug User Fee Act (PDUFA) Reauthorization","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":44486,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"THOMAS","last_name":"BATTAGLINI","suffix":"esq","suffix_display":"ESQ"},"covered_position":"Mike Enzi, Sr. Senator WY, Congressional Fellow","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Coverage Issues\nH.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009\nS. 254 Medicare Home Infusion Therapy Coverage Act of 2009\nH.R. 3590 Patient Protection and Affordable Care Act H.R. 4872 Health Care and Education Reconciliation Act of 2010\nH.R. 4213 Workers, State, and Business Relief Act of 2010\nH.R. 2847 Hiring Incentives to Restore Employment Act\nH.R. 4851 Continuing Extension Act of 2010","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":44486,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"THOMAS","last_name":"BATTAGLINI","suffix":"esq","suffix_display":"ESQ"},"covered_position":"Mike Enzi, Sr. Senator WY, Congressional Fellow","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Medical Research\nPrescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues\nAntibiotic Resistance Issues\nH.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR) H.R. 2937 MRSA Infection Prevention and Patient Protection Act\nS. 369 Preserve Access to Affordable Generics Act of 2009","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":44486,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"THOMAS","last_name":"BATTAGLINI","suffix":"esq","suffix_display":"ESQ"},"covered_position":"Mike Enzi, Sr. Senator WY, Congressional Fellow","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}